ESCRS - PP08.04 - Outcomes In Phaco-Dmek Vs Dmek And Phaco In 2 Times With Premium Iol

Outcomes In Phaco-Dmek Vs Dmek And Phaco In 2 Times With Premium Iol

Published 2023 - 41st Congress of the ESCRS

Reference: PP08.04 | Type: Free paper | DOI: 10.82333/j2k6-ye18

Authors: Antonio Cano-Ortiz* 1 , Álvaro Sánchez Ventosa 1 , Alberto Villarrubia 1 , Timoteo González Cruces 2 , Elisa Palacin 1 , Maria Dolores López-Perez 1 , Alberto Membrillo del Pozo 3 , Vanesa Diaz Mesa 2

1Cornea, refractive and external disease ,Arruzafa Hospital,Cordoba ,Spain, 2Arruzafa Hospital,Cordoba ,Spain, 3Cordoba University,Cordoba ,Spain

Purpose

To describe the functional results after implantation of Vivity (or Vivity toric) in patients requiring DMEK and cataract surgery in one or two procedure.

Setting

Arruzafa Ophthalmological Hospital, Cordoba, Spain.

Methods

Prospective, descriptive, double arm, 3 month follow up. 1 surgeon

The study comprised 30 eyes undergoing phacodmek surgery. Patients were separated into two groups: group 1 (15 patients; 15 eyes) received DMEK surgery and 3 month after phaco + vivity IOL and group 2 (15 patients; 15 eyes) received a phacodmek + vivty IOL procedure.

The inclusion criteria were cataract patients with Fuchs Dystrophy requiring endothelial transplant (DMEK) and phaco + IOL

Results

13 patients have completed the follow-up. 6 from group 1 and 7 from group 2. The UCDVA were 0.64±0.21 in group 1, and 0.60±0.17 in group 2. The CDVA were 0.94±0.19 and 0.82±0.14 respectively. No statistical differences in these parameters.

There were no differences in sphere, cylinder and spherical equivalent results

The postoperative endothelial cell count were 1332.16±203.82 in group 1, and 1928.85±408.43 with a p value of 0.007749.

Conclusions

The use of Vivity IOL in patients with Fuchs and DMEK seems to be a safe and effective option.

Phaco-DMEK is more respectful to the endothelium than DMEK and phaco in two separate procedures.

Performing phaco three months after DMEK doesn’t make us more predictable in sphere and astigmatism results.

Non-diffractive Premium platforms may be an option in patients with endothelial pathology and recovery after standardized DMEK